The DISRUPT Study Direct Lysis of Staph aureus Resistant Pathogen Trial - A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of

Grants and Contracts Details

StatusFinished
Effective start/end date12/15/21 → 7/13/23

Funding

  • ContraFect Corporation: $31,148.00